SARECYCLINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sarecycline hydrochloride and what is the scope of patent protection?
Sarecycline hydrochloride
is the generic ingredient in one branded drug marketed by Almirall and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sarecycline hydrochloride has seventy-one patent family members in twenty countries.
One supplier is listed for this compound.
Summary for SARECYCLINE HYDROCHLORIDE
International Patents: | 71 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 6 |
Patent Applications: | 12 |
What excipients (inactive ingredients) are in SARECYCLINE HYDROCHLORIDE? | SARECYCLINE HYDROCHLORIDE excipients list |
DailyMed Link: | SARECYCLINE HYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SARECYCLINE HYDROCHLORIDE
Generic Entry Date for SARECYCLINE HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SARECYCLINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Beijing Tiantan Hospital | Phase 2 |
NeuroDawn Pharmaceutical Co., Ltd. | Phase 2 |
Derm Research, PLLC | Phase 4 |
Pharmacology for SARECYCLINE HYDROCHLORIDE
Drug Class | Tetracycline-class Drug |
Mechanism of Action | P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SARECYCLINE HYDROCHLORIDE
US Patents and Regulatory Information for SARECYCLINE HYDROCHLORIDE
International Patents for SARECYCLINE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Turkey | 201911086 | ⤷ Subscribe | |
Denmark | 2707003 | ⤷ Subscribe | |
Slovenia | 2120963 | ⤷ Subscribe | |
Canada | 2835876 | SELS CRISTALLINS D'AMIDE DE L'ACIDE (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO- 3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]- 1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTACENE-2-CARBOXYLIQUE ET PROCEDES D'UTILISATION ASSOCIES (CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(METHYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME) | ⤷ Subscribe |
European Patent Office | 2450347 | Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites (Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections) | ⤷ Subscribe |
European Patent Office | 3812372 | DÉRIVÉS DE SANCLYCINE SUBSTITUÉS PAR 7-HÉTÉROCYCLYL POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES, VIRALES, ET PARASITAIRES (P.E. MALARIA) OU MALADIES INFLAMMATOIRES (7-HETEROCYCLYL SUBSTITUTED SANCYCLINE DERIVATIVES FOR TREATING BACTERIAL, VIRAL AND PARASITIC INFECTIONS (E.G. MALARIA) OR INFLAMMATORY DISEASES) | ⤷ Subscribe |
Japan | 6061897 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
SARECYCLINE HYDROCHLORIDE Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.